Table 3.
Univariate and multivariate analysis for risk factors of severe type in patients with COVID-19
| Clinical characteristics | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| OR (95%CI) | P-value a | OR (95%CI) | P-value a | |
| Age(years) | ||||
| ≤ 65 | Reference | Reference | ||
| > 65 | 7.66 (2.73,21.46) | < 0.001 | 9.72 (2.92,32.31) | < 0.001 |
| Comorbidity | ||||
| Without | Reference | |||
| Any | 1.13 (0.5,2.56) | 0.779 | ||
| Lymphocyte (× 109/L) | ||||
| > 1.1 | Reference | Reference | ||
| ≤ 1.1 | 4.81 (2,11.58) | < 0.001 | 3.42 (1.24,9.41) | 0.017 |
| Unknown | 0.49 (0.06,4.09) | 0.511 | 0.28 (0.01,8.38) | 0.465 |
| Eosinophils, × 109 /L | ||||
| > 0.02 | Reference | |||
| ≤ 0.02 | 244,632,670.97 (0, Inf) | 0.988 | ||
| Unknown | 0.87 (0.26,2.87) | 0.821 | ||
| AST, U/L | ||||
| ≤ 35 | Reference | Reference | ||
| > 35 | 4.99 (2.02,12.31) | < 0.001 | 3.19 (1.11,9.19) | 0.032 |
| Unknown | 0.9 (0.18,4.41) | 0.899 | 2.17 (0.14,34.37) | 0.584 |
| Albumin, g/L | ||||
| > 40 | Reference | |||
| ≤ 40 | 2.12 (0.46,9.87) | 0.339 | ||
| Unknown | 0.5 (0.04,6.12) | 0.588 | ||
| Total bilirubin, umol/L | ||||
| ≤ 24 | Reference | |||
| > 24 | 13,242,969.58 (0, Inf) | 0.987 | ||
| Unknown | 0.39 (0.16,0.97) | 0.044 | ||
| Ca2+, mmol/L | ||||
| > 2 | Reference | |||
| ≤ 2 | 3.75 (0.73,19.14) | 0.112 | ||
| Unknown | 0.27 (0.1,0.75) | 0.012 | ||
AST aspartate aminotransferase
aLogistic regression analysis